AstraZeneca Results Presentation Deck
Core profit and loss
Core EPS above FY 2021 guidance
Total Revenue
- Product Sales
- Collaboration Revenue
Gross margin
Operating expenses¹
- R&D expenses
- SG&A expenses
Other operating income
Operating profit
Tax rate
EPS
FY 2021
$m
37,417
36,541
876
74.2%
19,537
7,987
11,104
1,492
9,928
16.6%
$5.29
CER change
%
38
38
20
(4.7) pp
22
33
15
(4)
41
37
% total
revenue
100
98
2
52
21
30
4
27
Q4 2021
$m
12,011
11,498
513
74.3%
5,888
2,396
3,368
146
3,318
16.2%
$1.67
13 Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales.
1. Includes distribution expenses. R&D = research and development; SG&A = sales, general and administration; pp = percentage points; n/m = growth rate not meaningful.
CER change
%
63
65
29
(1.9) pp
26
40
18
(78)
94
74
% total
revenue
100
96
4
49
20
28
1
28View entire presentation